Company: IMRX
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077655
Chunk: 48

Company: Immuneering Corp
Filing Date: 2025-08-13
Form: S-3
Chunk 48
---
,” “might,” “likely,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms include forward-looking statements that involve risks and uncertainties. All statements other than statements of historical fact contained in this prospectus supplement and the documents incorporated by reference in this prospectus supplement, including without limitation statements regarding our plans to develop, manufacture and commercialize our product candidates (including whether as potential monotherapies or in combination with other therapeutic agents), the design, timing, disclosure of data, or outcome of our ongoing or planned preclinical studies or clinical trials involving atebimetinib (IMM-1-104), any of our other pipeline product candidates and any future product candidates, the clinical utility of our product candidates when administered alone or in combination with other therapeutic agents, the filing with, and approval by, regulatory authorities of our product candidates, the sufficiency of funds to operate our business and related expected cash runway, our ability to continue as a going concern, our plans regarding raising additional capital and the use of proceeds from this offering, are forward-looking statements.

The forward-looking statements in this prospectus supplement and the documents incorporated by reference in this prospectus supplement are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those projected in the forward-looking statements, including, but not limited to, those described in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are incorporated by reference into this prospectus supplement. These risks and uncertainties include, but are not limited to:

•

our limited operating history;

•

our history of operating losses;

•

our ability to continue as a going concern for a period of at least one year from the date of issuance of the financial statements appearing within the Quarterly Report on Form 10-Q filed for the period ended June 30, 2025 and our future capital needs;

•

our ability to raise the substantial additional capital that will be required to finance our operations;

•

the difficulty of obtaining regulatory approval for any of our current or future product candidates;

•

our ability to submit an Investigational New Drug application, or IND, or IND amendments or comparable documents in foreign jurisdictions in order to commence